Yan Shuai, Hao Min, Yang Huiju, Sun Mingming, Wu Bensheng, Yue Yinzi, Wang Xiaopeng
Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China; Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, China.
School of Pharmacy, Zhejiang Chinese Medicine University, Hangzhou, China.
Ann Palliat Med. 2020 Sep;9(5):2837-2852. doi: 10.21037/apm-20-280. Epub 2020 Aug 21.
In China, Zhishi (Aurantii Fructus Immaturus) - Baizhu (Atractylodis Macrocephalae Rhizoma) is a well-known herb pair used to treat gastrointestinal motility disorders for thousands of years, and it has especially shown a definite advantage in the treatment of slow transit constipation (STC). However, the mechanism of Zhishi-Baizhu (ZSBZ) in the treatment of STC remains unclear. In this study, plasma metabolomics research combined with metabolic pathway analysis has been used to illuminate the potential mechanism of its effects against STC.
Parameters of intestinal transit ratio, plasma motilin (MTL), substance P (SP), adenosine triphosphate (ATP), histological alteration of the colon and MLCK expression in the colon were detected to evaluate the effects with respect to STC. Principal component analysis (PCA) was used to investigate the global metabolite alterations, while orthogonal partial least squares discriminant analysis (OPLS-DA) and t-test were used to filter potential metabolite markers. Moreover, metabolic pathway analysis was employed.
Oral administration of ZSBZ significantly prevented the development of STC. It increased the expression of MTL and SP in serum, as well as the expression of ATP and MLCK in the colon. ZSBZ administration alleviated symptoms in loperamide-induced constipated rats, evidenced by the increase of intestinal transit ratio. Futhermore, 9 potential biomarkers of STC were screened, and the levels were all reversed to different degrees after ZSBZ administration. Metabolic pathway analysis showed that the improvement of STC by ZSBZ was mainly related to caffeine and vitamin B6 metabolism.
Our study identifies the metabolic networks of constipated rats and demonstrates the efficacy of this metabolomics approach to systematically study the therapeutic effects of ZSBZ on constipation.
在中国,枳实 - 白术是一对著名的药对,用于治疗胃肠动力障碍已有数千年历史,尤其在治疗慢传输型便秘(STC)方面显示出明显优势。然而,枳实 - 白术(ZSBZ)治疗STC的机制尚不清楚。在本研究中,采用血浆代谢组学研究结合代谢途径分析来阐明其治疗STC的潜在机制。
检测肠道传输率、血浆胃动素(MTL)、P物质(SP)、三磷酸腺苷(ATP)、结肠组织学改变以及结肠中肌球蛋白轻链激酶(MLCK)表达等参数,以评估对STC的影响。主成分分析(PCA)用于研究整体代谢物变化,而正交偏最小二乘法判别分析(OPLS - DA)和t检验用于筛选潜在的代谢物标志物。此外,还进行了代谢途径分析。
口服ZSBZ可显著预防STC的发展。它增加了血清中MTL和SP的表达,以及结肠中ATP和MLCK的表达。ZSBZ给药缓解了洛哌丁胺诱导的便秘大鼠的症状,肠道传输率增加证明了这一点。此外,筛选出9种STC的潜在生物标志物,ZSBZ给药后其水平均有不同程度的逆转。代谢途径分析表明,ZSBZ对STC的改善主要与咖啡因和维生素B6代谢有关。
我们的研究确定了便秘大鼠的代谢网络,并证明了这种代谢组学方法在系统研究ZSBZ对便秘治疗效果方面的有效性。